Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Suppressing Cancer Transcriptional Regulatory Complex Activity May Depend on Inositol Phosphate Signaling

By LabMedica International staff writers
Posted on 24 Jan 2012
A recent paper detailed the structure of a transcriptional regulatory complex, which revealed a link between inositol phosphate signaling and the regulation of histone deacetylase enzymes.

Histone deacetylase enzymes (HDACs) are emerging cancer drug targets. More...
They regulate gene expression by removing acetyl groups from lysine residues in histone tails, resulting in chromatin condensation.

Investigators at the University of Leicester (United Kingdom) described the structure of a complex between an HDAC and a corepressor, namely, human HDAC3 with the deacetylase activation domain (DAD) from the human SMRT co-repressor in the January 9, 2012, online edition of the journal Nature.

The structure revealed two remarkable features. First, the SMRT-DAD underwent a large structural rearrangement on forming the complex. Second, there was an essential inositol tetraphosphate molecule -- d-myo-inositol-(1,4,5,6)-tetrakisphosphate -- acting as an “intermolecular glue” between the two proteins.

Senior author Dr. John Schwabe, professor of biochemistry at the University of Leicester, said, “We have discovered a completely new and unexpected link between inositol phosphate signaling (in this case IP4) and the regulation of histone deacetylase enzymes, and hence transcriptional repression or gene silencing. In simple terms, we have shown that IP4 acts as a natural signaling molecule to regulate histone deacetylase enzymes, which play a key role in regulating gene expression. Apart from the considerable intellectual importance of understanding how transcription is regulated, repression complexes are important therapeutic targets for a number of cancers including several types of leukemia.”

“Our research identifies several new means to potentially target histone deacetylase enzymes therapeutically, either by using drugs to prevent IP4 binding to the enzyme or by interfering with the pathway through which the body makes IP4,” said Dr. Schwabe. “Thus, this work opens up a whole new area of research with potential for new drugs and a new approach to targeting histone deacetylase enzymes.”

Related Links:

University of Leicester





Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.